A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01851746
Recruitment Status : Unknown
Verified May 2013 by HB Cai, Wuhan University. Recruitment status was: Active, not recruiting
Evidence of the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer. [ Time Frame: from pre-chemotherapy to 4-6 weeks post-chemotherapy ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
residents of a certain town
age between 18 and 70 years old
singed the information consent form
Expected survival time >3 months
Recurrence for at least 6 months after receiving initial platinum-based chemotherapy and without cytoreductive surgery indications.
Recurrence within 6 months after receiving initial platinum-based chemotherapy
without radiographic evidence for tumor recurrence
receiving other chemotherapy, hormone therapy, immunotherapy, or radiation therapy